The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
The approval further strengthens the Potassium Chloride franchise for the company.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Strides is the first Indian company to get approval for the product.
Both manufacturing facilities are based out of Benguluru, India
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)